The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...
Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback